General Information of the Drug (ID: M6APDG01894)
Name
5,6,7,8-tetrahydroanthracene-1,4-dione
Synonyms
CHEMBL508233; 5,6,7,8-tetrahydroanthracene-1,4-dione; SCHEMBL11038167
    Click to Show/Hide
Status
Investigative
Structure
Formula
C14H12O2
InChI
1S/C14H12O2/c15-13-5-6-14(16)12-8-10-4-2-1-3-9(10)7-11(12)13/h5-8H,1-4H2
InChIKey
DWXLNXHEUIUNRF-UHFFFAOYSA-N
PubChem CID
44582382
TTD Drug ID
D0SI7S
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
M-phase inducer phosphatase 2 (MPIP2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary M-phase inducer phosphatase 2 (MPIP2) is a therapeutic target for 5,6,7,8-tetrahydroanthracene-1,4-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5,6,7,8-tetrahydroanthracene-1,4-dione through regulating the expression of M-phase inducer phosphatase 2 (MPIP2). [1], [2]
References
Ref 1 METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression. Exp Hematol Oncol. 2022 Mar 14;11(1):14. doi: 10.1186/s40164-022-00256-3.
Ref 2 Handbook of Assay Development in Drug Discovery, Lisa K. Minor, 2013. Page(11).